LB Pharmaceuticals Inc.(LBRX:US)
Market Cap$1.054B
Key Metrics
Price$36.74
Revenue (TTM)$0
Holders Revenue (TTM)-
Gross Profit (TTM)-
Earnings (TTM)-$38.95M
EBITDA (TTM)-$46.35M
Op. Margin (TTM)-
Dividend Yield-
Holders Yield-
Cash on hand$320.68M
Total Assets$393.48M
Net Assets$378.69M
Total Debt$3.47M
Key Metrics
Price$36.74
Revenue (TTM)$0
Holders Revenue (TTM)-
Gross Profit (TTM)-
Earnings (TTM)-$38.95M
EBITDA (TTM)-$46.35M
Op. Margin (TTM)-
Dividend Yield-
Holders Yield-
Cash on hand$320.68M
Total Assets$393.48M
Net Assets$378.69M
Total Debt$3.47M
Financials
| Name | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
Cost of Revenue | - | - | - | - | - | - | - | - |
Gross Profit | - | - | - | - | - | - | - | - |
| $22.1M | $13.87M | $5.25M | $4.86M | $5.54M | $16.08M | $26.58M | $16.63M | |
| Research and Development | $14.65M | $8.48M | $2.42M | $2.42M | $376K | $10.66M | $24.46M | $15.67M |
| Selling, General, and Administrative | $7.46M | $5.39M | $2.83M | $2.44M | $5.16M | $5.42M | $2.12M | $957K |
| Other Operating Expenses | - | - | - | - | - | - | - | - |
Operating Income | -$22.1M | -$13.87M | -$5.25M | -$4.86M | -$5.54M | -$16.08M | -$26.58M | -$16.63M |
| $3.05M | $2.4M | $1.69M | -$12K | $469K | $1.9M | -$1.12M | $474K | |
| Non-Operating Interest Income | $2.85M | $2.8M | $707K | $177K | $298K | $384K | $411K | $628K |
| Non-Operating Interest Expense | - | - | - | - | - | - | - | $0 |
| Other Income/Expense | $200K | -$401K | $983K | -$189K | $171K | $1.52M | -$1.53M | -$154K |
Income Before Tax | -$19.05M | -$11.47M | -$3.56M | -$4.87M | -$5.07M | -$14.18M | -$27.7M | -$16.15M |
Income Tax | $0 | $1K | $0 | $0 | $1K | $0 | $0 | $0 |
Net Income | -$19.05M | -$11.47M | -$3.56M | -$4.87M | -$5.07M | -$14.18M | -$27.7M | -$16.15M |
Minority Interests | - | - | - | - | - | - | - | - |
Preferred Stock Dividends | - | - | - | - | - | - | - | - |
Net Income to Common | -$19.05M | -$11.47M | -$3.56M | -$4.87M | -$5.07M | -$14.18M | -$27.7M | -$16.15M |
Shares Outstanding (Basic) | 28.24M | 25.41M | 5.81M | - | - | 3.54M | - | 3.54M |
Shares Outstanding (Diluted) | 28.24M | 25.41M | 5.81M | - | - | 3.54M | - | 3.54M |
EPS (Basic) | -$0.67 | -$0.45 | -$0.61 | - | - | -$4.01 | - | -$4.56 |
EPS (Diluted) | -$0.67 | -$0.45 | -$0.61 | - | - | -$4.01 | - | -$4.56 |
EBIT | -$22.1M | -$13.87M | -$5.25M | -$4.86M | -$3.81M | -$16.08M | -$27.05M | -$16.15M |
EBITDA | -$22.22M | -$13.38M | -$6.15M | -$4.59M | -$3.9M | -$17.6M | -$25.52M | -$16M |